Generali Asset Management SPA SGR Decreases Position in Merck & Co., Inc. $MRK

Generali Asset Management SPA SGR lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 308,173 shares of the company’s stock after selling 32,367 shares during the period. Merck & Co., Inc. accounts for 0.7% of Generali Asset Management SPA SGR’s investment portfolio, making the stock its 26th biggest holding. Generali Asset Management SPA SGR’s holdings in Merck & Co., Inc. were worth $32,438,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Barnes Dennig Private Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares during the last quarter. United Financial Planning Group LLC purchased a new stake in Merck & Co., Inc. during the third quarter valued at about $31,000. Wealth Watch Advisors INC purchased a new stake in Merck & Co., Inc. during the third quarter valued at about $34,000. Dunhill Financial LLC lifted its holdings in Merck & Co., Inc. by 83.0% during the third quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after purchasing an additional 190 shares during the last quarter. Finally, Silicon Valley Capital Partners lifted its holdings in Merck & Co., Inc. by 160.5% during the third quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock valued at $35,000 after purchasing an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In other news, CMO Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Guggenheim upped their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. Wells Fargo & Company dropped their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. TD Cowen upped their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Merck & Co., Inc. in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Trading Down 1.2%

Shares of Merck & Co., Inc. stock opened at $112.22 on Friday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a market cap of $277.17 billion, a price-to-earnings ratio of 31.61, a PEG ratio of 2.56 and a beta of 0.18. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 1.02. The company’s 50-day moving average price is $117.07 and its 200-day moving average price is $108.31.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the firm posted $2.22 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a Science paper describing a scalable, enzyme-driven synthesis for its investigational oral PCSK9 inhibitor enlicitide decanoate — a notable R&D milestone that supports the commercial potential of a new oral lipid-lowering modality. Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
• Positive Sentiment: Merck’s BioReliance unit inked a five‑year deal to be the sole testing provider for Genetix Biotherapeutics’ FDA‑approved gene therapies — adds recurring, commercial‑stage service revenue and reinforces Merck’s role in cell & gene therapy commercialization. Merck Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
• Positive Sentiment: Merck completed the Terns acquisition to expand its chronic myeloid leukemia (CML) pipeline; the deal and FDA breakthrough designation for a TERN asset strengthen oncology pipeline optionality. MSD concludes Terns acquisition to expand CML pipeline
• Positive Sentiment: Analysts and brokers showed support after Merck’s Q1 beat — one analyst nudged the price target higher and BMO reiterated a buy — giving near‑term fundamental backing to the stock. Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates BMO Capital Remains a Buy on Merck & Company (MRK)
• Neutral Sentiment: Merck Animal Health selected Salesforce’s Agentforce Life Sciences for omnichannel engagement — a strategic IT/customer‑engagement win but with modest near‑term financial impact versus drug/cell‑therapy drivers. Salesforce AI Win With Merck Highlights Real World Platform Adoption
• Neutral Sentiment: Citigroup initiated coverage with a “neutral” rating and a $125 price target — supportive of upside but not a strong buy signal; highlights mixed analyst views on valuation vs. growth. Citigroup Initiates Coverage
• Negative Sentiment: Sector competitors posted robust oncology and diabetes results (J&J oncology growth; Eli Lilly’s blockbuster Mounjaro sales), underscoring competitive pressure in key therapeutic areas and possibly contributing to profit‑taking and relative valuation compression for Merck. Sector Competitive Moves Darzalex, Erleada & New Drugs Keep J&J’s Oncology Engine Charged in Q1 Eli Lilly Now Has the World’s Best-Selling Drug — But Does That Make the Stock a No-Brainer Buy?

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.